148 related articles for article (PubMed ID: 25470699)
1. Cancer-drug discovery--let's get ready for the next period.
Longo DL
N Engl J Med; 2014 Dec; 371(23):2227-8. PubMed ID: 25470699
[No Abstract] [Full Text] [Related]
2. First-line crizotinib in ALK-positive lung cancer.
Solomon BJ; Mok T
N Engl J Med; 2015 Feb; 372(8):782. PubMed ID: 25693021
[No Abstract] [Full Text] [Related]
3. Targeted therapies: new standard for ALK-positive NSCLC.
Hutchinson L
Nat Rev Clin Oncol; 2015 Feb; 12(2):66. PubMed ID: 25560531
[No Abstract] [Full Text] [Related]
4. First-line crizotinib in ALK-positive lung cancer.
Alkan A; Köksoy EB; Utkan G
N Engl J Med; 2015 Feb; 372(8):781-2. PubMed ID: 25693023
[No Abstract] [Full Text] [Related]
5. First-line crizotinib in ALK-positive lung cancer.
Tural D; Kilickap S
N Engl J Med; 2015 Feb; 372(8):781. PubMed ID: 25693022
[No Abstract] [Full Text] [Related]
6. Crizotinib in ALK-positive lung cancer.
Girard N
Lancet Oncol; 2012 Oct; 13(10):962-3. PubMed ID: 22954506
[No Abstract] [Full Text] [Related]
7. Hope without hype: EML4-ALK inhibition for treatment of lung cancer.
Govindan R
Lancet Oncol; 2011 Oct; 12(11):983-4. PubMed ID: 21933750
[No Abstract] [Full Text] [Related]
8. [Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No].
Girard N
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S96-9. PubMed ID: 26118885
[TBL] [Abstract][Full Text] [Related]
9. Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.
Kaneda H; Okamoto I; Nakagawa K
J Thorac Oncol; 2013 Apr; 8(4):e32-3. PubMed ID: 23486271
[No Abstract] [Full Text] [Related]
10. More than just an oncogene translocation and a kinase inhibitor: Kevin's story.
Costa DB
J Clin Oncol; 2012 Jan; 30(1):110-2. PubMed ID: 22067391
[No Abstract] [Full Text] [Related]
11. Cross-over-it's a feature, not a bug.
Engelsberg A
Ann Oncol; 2015 Sep; 26(9):2000-2002. PubMed ID: 26078468
[TBL] [Abstract][Full Text] [Related]
12. Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.
Costa DB; Kobayashi S
J Thorac Oncol; 2012 Mar; 7(3):623-5. PubMed ID: 22334013
[No Abstract] [Full Text] [Related]
13. Alectinib surpasses crizotinib for untreated ALK-positive NSCLC.
Gilbert JA
Lancet Oncol; 2017 Jul; 18(7):e377. PubMed ID: 28625556
[No Abstract] [Full Text] [Related]
14. Lung cancer: Resolving resistance to ALK-targeted therapy.
Hutchinson L
Nat Rev Clin Oncol; 2016 Feb; 13(2):64. PubMed ID: 26806320
[No Abstract] [Full Text] [Related]
15. Crizotinib Resensitization by Compound Mutation.
Bordi P; Del Re M; Tiseo M
N Engl J Med; 2016 May; 374(18):1790. PubMed ID: 27144863
[No Abstract] [Full Text] [Related]
16. Crizotinib Resensitization by Compound Mutation.
Shaw AT; Engelman JA
N Engl J Med; 2016 May; 374(18):1790-1. PubMed ID: 27144862
[No Abstract] [Full Text] [Related]
17. Resistance: Crizotinib makes a comeback.
Shipman L
Nat Rev Cancer; 2016 Feb; 16(2):69. PubMed ID: 26797648
[No Abstract] [Full Text] [Related]
18. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
Duruisseaux M; Besse B; Cadranel J; Pérol M; Mennecier B; Bigay-Game L; Descourt R; Dansin E; Audigier-Valette C; Moreau L; Hureaux J; Veillon R; Otto J; Madroszyk-Flandin A; Cortot A; Guichard F; Boudou-Rouquette P; Langlais A; Missy P; Morin F; Moro-Sibilot D
Oncotarget; 2017 Mar; 8(13):21903-21917. PubMed ID: 28423535
[TBL] [Abstract][Full Text] [Related]
19. [Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].
Giroux Leprieur E; Wislez M
Bull Cancer; 2016 Feb; 103(2):125-6. PubMed ID: 26822904
[No Abstract] [Full Text] [Related]
20. Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.
Peled N; Zach L; Liran O; Ilouze M; Bunn PA; Hirsch FR
J Thorac Oncol; 2013 Dec; 8(12):e112-3. PubMed ID: 24389447
[No Abstract] [Full Text] [Related]
[Next] [New Search]